Medications for Neuromyelitis Optica Spectrum Disorder With Antiaqp4 Antibodies

4 results

  • enspryng

    (Satralizumab)
    Genentech Inc.
    ENSPRYNG is indicated for treating neuromyelitis optica spectrum disorder (NMOSD) in adult patients who test positive for anti-aquaporin-4 (AQP4) antibodies.

  • soliris

    (ECULIZUMAB)
    Alexion Pharmaceuticals Inc.
    SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.

  • ultomiris

    (ravulizumab)
    Alexion Pharmaceuticals Inc.
    ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.

  • uplizna

    (Inebilizumab)
    Horizon Therapeutics USA, Inc.
    UPLIZNA is indicated for treating neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive and for treating Immunoglobulin G4-related disease (IgG4-RD) in adult patients.